Pre-Open Stock Movers 06/26: (MDCA) (VXRT) (GPS) Higher; (SHIP) (SOLY) (NKE) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Stocks face worst month since September, yen swings after BoJ
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Argus Reiterates Buy Rating on Nike (NKE) Following 4Q
June 30, 2020 7:26 AM EDTArgus analyst John Staszak reiterated a Buy rating and $115.00 price target on Nike (NYSE: NKE) following the company's 4Q earnings report. Nike reported fiscal 4Q20 revenue and EPS that missed estimates. Revenue of $6.3 billion. the consensus estimate had called for revenue of $7.3 billion. The adjusted... More
Altimmune (ALT) Reports First Patient Dosing in Phase 1b Clinical Trial of NasoShield
June 30, 2020 7:04 AM EDTAltimmune, Inc. (NASDAQ: ALT) today announced dosing of the first patient in the Companys Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. The NasoShield program is being developed under a contract with the Biomedical Advanced Research and Development Authority (BARDA), with a total potential value of $133.7 million if all options in the contract (HHSO100201600008C) are exercised.
NasoShield is the only single dose anthrax vaccine in development that is supported by BARDA, and has the potential to provide a significant improvement over the available two- and... More
